Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer

A 56-year old woman with BRCA-associated breast cancer and recurrent ovarian cancer was treated with a poly (ADP-ribose) polymerase enzyme (PARP) inhibitor, rucaparib, in the setting of dialysis-dependence which required dose modification. Rucaparib trough levels were obtained before and after dialy...

Descripción completa

Detalles Bibliográficos
Autores principales: Harold, Justin A., Free, Stephanie C., Bradley, William H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223187/
https://www.ncbi.nlm.nih.gov/pubmed/30426062
http://dx.doi.org/10.1016/j.gore.2018.10.011
_version_ 1783369365776760832
author Harold, Justin A.
Free, Stephanie C.
Bradley, William H.
author_facet Harold, Justin A.
Free, Stephanie C.
Bradley, William H.
author_sort Harold, Justin A.
collection PubMed
description A 56-year old woman with BRCA-associated breast cancer and recurrent ovarian cancer was treated with a poly (ADP-ribose) polymerase enzyme (PARP) inhibitor, rucaparib, in the setting of dialysis-dependence which required dose modification. Rucaparib trough levels were obtained before and after dialysis and a clinically significant disease response was appreciated.
format Online
Article
Text
id pubmed-6223187
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-62231872018-11-13 Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer Harold, Justin A. Free, Stephanie C. Bradley, William H. Gynecol Oncol Rep Case Report A 56-year old woman with BRCA-associated breast cancer and recurrent ovarian cancer was treated with a poly (ADP-ribose) polymerase enzyme (PARP) inhibitor, rucaparib, in the setting of dialysis-dependence which required dose modification. Rucaparib trough levels were obtained before and after dialysis and a clinically significant disease response was appreciated. Elsevier 2018-10-28 /pmc/articles/PMC6223187/ /pubmed/30426062 http://dx.doi.org/10.1016/j.gore.2018.10.011 Text en © 2018 Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Harold, Justin A.
Free, Stephanie C.
Bradley, William H.
Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer
title Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer
title_full Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer
title_fullStr Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer
title_full_unstemmed Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer
title_short Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer
title_sort pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with brca associated breast and recurrent ovarian cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223187/
https://www.ncbi.nlm.nih.gov/pubmed/30426062
http://dx.doi.org/10.1016/j.gore.2018.10.011
work_keys_str_mv AT haroldjustina pharmacokineticsandclinicalresponsetosingleagentrucaparibinadialysisdependentpatientwithbrcaassociatedbreastandrecurrentovariancancer
AT freestephaniec pharmacokineticsandclinicalresponsetosingleagentrucaparibinadialysisdependentpatientwithbrcaassociatedbreastandrecurrentovariancancer
AT bradleywilliamh pharmacokineticsandclinicalresponsetosingleagentrucaparibinadialysisdependentpatientwithbrcaassociatedbreastandrecurrentovariancancer

Ejemplares similares